Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Inclusion criteria

• Locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC)
• Epidermal Growth Factor Receptor (EGFR) mutation-positive results per the institution's testing methodology
• Male or female patients age >=18 years
• Adequate organ function, defined as all of the following:
• Absolute neutrophil count (ANC) >1500/mm3
• Platelet count>75,000/mm3
• Serum creatinine 45ml/min
• Total bilirubin <1.5 times upper limit of (institutional) normal
• Aspartate Amino Transferase (AST) or Alanine Amino Transferase (ALT) < three times the upper limit of (institutional) normal (if related to liver metastases < five times ULN)
• Eastern Cooperative Oncology Group (ECOG) score between 0-2
• Written informed consent by patient or guardian prior to admission into the trial that is consistent with International Conference on Harmonization (ICH)- Good Clinical Practice (GCP) guidelines and local law
• Recovery from any previous therapy related toxicity to <=CTCAE Grade 1 at study entry (except for stable sensory neuropathy <=CTCAE Grade 2 and alopecia)

Exclusion criteria

• Prior treatment with an EGFR tyrosine kinase inhibitor (TKI)
• Hormonal anti-cancer treatment within 2 weeks prior to start of trial treatment (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer permitted)
• Radiotherapy within 28 days prior to drug administration, except as follows:
• Palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and
• Single dose palliative treatment for symptomatic metastases outside above allowance to be discussed with sponsor prior to enrolling
• Major surgery within 4 weeks before starting trial treatment or scheduled for surgery during the projected course of the trial
• Known hypersensitivity to afatinib or any of its excipients
• History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to starting trial treatment
• Women of Child-Bearing Potential (WOCBP) and men who are able to father a child, unwilling to use adequate contraception prior to trial entry, for the duration of trial participation and for at least 2 weeks after treatment has ended
• Childbearing potential who:
• are nursing or
• are pregnant or
• are not using an acceptable method of birth control, or do not plan to continue using this method throughout the trial and/or do not agree to submit to pregnancy testing required by this protocol
• Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patients ability to comply with the trial or interfere with the evaluation of safety for the trial drug
• Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured
• Requiring treatment with any of the prohibited concomitant medications that cannot be stopped for the duration of trial participation
• Known pre-existing interstitial lung disease
• Presence of poorly controlled gastrointestinal disorders that could affect the absorption of the trial drug (e.g. Crohn's disease, ulcerative colitis, malabsorption, or Common Terminology Criteria grade =2 diarrhea of any aetiology) based on investigator assessment
• Active hepatitis B infection (defined as presence of Hepatitis B (HepB) sAg and/or HepB DNA), active Hepatitis C (HEP C) infection (defined as presence of Hep C RNA) and/or known Human Immunodeficiency Virus (HIV) carrier
• Meningeal carcinomatosis
• Symptomatic brain metastases (patients with asymptomatic b